Novel potential approach to prevent infection in patients with liver failureEurekAlert (press release)Findings published in the American Association for the Study of Liver Diseases journal, Hepatology, indicate that infection, the commonest cause of mo…
Engineered anti-toxin antibodies improve efficacyEurekAlert (press release)The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent stu…
|
Researchers find comparable long-term outcomes between diastolic and systolic …
Science Codex (Boston) – A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as … Participation rate problem in rehabStarPhoenix |
|
Researchers find comparable long-term outcomes between diastolic and systolic …
EurekAlert (press release) (Boston) – A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as … |
|
Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose …
Multiple Sklerose News: Startseite In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko … |
|
WEEKEND PLAN: Tune in for some music
The Reporter Admission is free and donations are welcome. Email. info@lansdalehistory.org. … Adam Dieffenbach performs a set of winter jazz, as part of the Indian Valley Public Library’s Second Fridays series, at 7:30 p.m. Friday at the library’s reading room … |
Multiple Sklerose News: Startseite |
Was hat sich 2013 in der MS-Therapie getan?
Multiple Sklerose News: Startseite In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko … |
Zymeworks pockets $15M, woos Lilly with its double-barreled antibodiesFierceBiotechUnder the deal, Lilly gets a worldwide license to the technology and commercial rights to any antibodies derived from the partnership, while Zymeworks snags an undisclos…
The Globe and Mail |
When organ donation relies on Facebook, something is wrong
The Globe and Mail That some Canadians are turning to social media in search of donors indicates the troubled state of organ donation in this country. The deceased donation … The primary motive for becoming an organ donor is to help someone else. One donor’s generosity … Website to be launched on Jan 26 to promote organ donationIBNLive |
|
Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies
Genetic Engineering News Zymeworks has entered into a worldwide licensing and collaboration agreement with ImClone Systems, a wholly owned subsidiary of Eli Lilly, to develop a number of bi-specific antibody oncology therapeutics using Zymeworks’ Azymetric™ platform. Zymeworks Announces $15.0 Million Private Placement Financing to Advance …The Herald | HeraldOnline.com (press release) Zymeworks, ImClone Systems partner to develop novel bi-specific antibody …News-Medical.net |